DiaMedica Therapeutics (DMAC) Net Equity Issued and Repurchased (2020 - 2025)

DiaMedica Therapeutics (DMAC) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $11.8 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $11.8 million; the trailing twelve-month figure through Dec 2025 stood at $43.3 million (up 1082150.0% YoY), and the FY2025 full-year result was $43.3 million, up 268.45% from the prior year.
• Net Equity Issued and Repurchased slipped to $11.8 million in Q4 2025 per DMAC's latest filing, from $31.5 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $31.5 million in Q3 2025 and bottomed at -$18000.0 in Q4 2021.
• Historically, Net Equity Issued and Repurchased has averaged $14.6 million across 3 years, with a median of $11.8 million in 2025.
• The widest YoY moves for Net Equity Issued and Repurchased: up 73.13% in 2021, down 40.95% in 2021.
• Over 3 years, Net Equity Issued and Repurchased stood at -$18000.0 in 2021, then soared by 77.78% to -$4000.0 in 2023, then surged by 293975.0% to $11.8 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $11.8 million, $31.5 million, and -$4000.0 for Q4 2025, Q3 2025, and Q3 2023 respectively.